Don’t let the high cost of brand specialty prostate cancer therapy stand between you and the treatment you need. We help eligible patients access Erleada (apalutamide) for as little as $69.95 per month through the manufacturer’s Patient Assistance Program.
The Erleada Prescription Assistance Program is a manufacturer-sponsored initiative that provides Erleada at little or no medication cost to qualifying patients based on income and insurance status. The program is designed for prostate cancer patients who are uninsured or underinsured, as well as Medicare Part D beneficiaries.
Navigating the program on your own means dealing with eligibility verification, oncology-team coordination, prior-authorization documentation, specialty pharmacy logistics, and renewal deadlines.
AffordMyPrescriptions eliminates that burden. For a flat $69.95 per month, our Patient Advocates handle every step of your enrollment, from initial application through ongoing refill coordination and annual re-certification — so you focus on your treatment, not paperwork.
| Pharmacy(With Coupon) | PrIce (30-Day)* | You Save W/ Us |
|---|---|---|
| Walgreens | ~$14,500.00 | Save ~$14,430/mo |
| CVS Pharmacy | ~$15,000.00 | Save ~$14,930/mo |
| Walmart | ~$13,800.00 | Save ~$13,730/mo |
| Costco | ~$13,500.00 | Save ~$13,430/mo |
| Specialty Pharmacy | ~$13,500.00 | Save ~$13,430/mo |
*Just a heads-up — retail prices are estimates based on public data and vary by pharmacy. AffordMyPrescriptions Advocacy Service bypasses this by using drug manufacturer programs to secure your medication directly at no cost or retail price.
1 Medications
2 Medications
3 Medications
4+ Medications
The Patient Assistance Program is free to apply for and provides Erleada at no medication cost if approved. But the process involves detailed applications, oncology-team coordination, specialty pharmacy logistics, and ongoing renewal management. Our $69.95/month service covers full advocacy.
Complete a simple eligibility form so our team can determine if you may qualify for medication assistance programs.
Our specialists help gather documentation, complete applications, and coordinate with program providers.
Once approved, you may receive your medication through the assistance program while we help manage ongoing paperwork and renewals.
Many patients try discount cards first. Here’s why the Patient Assistance Program through AffordMyPrescriptions is the better long-term solution for Erleada:
We manage all paperwork, refills, and annual renewals
Eligibility is generally determined by annual household income and insurance status. Most programs follow guidelines that include limits of up to $40,000 for individuals, $60,000 for couples, and $100,000 for larger families. Because requirements vary by program and household, we encourage you to contact AffordMyPrescriptions directly so we can review your specific situation and determine if you qualify for Erleada assistance.
Not sure if you qualify? Our pre-qualification check is completely free. If we can’t help, you won’t be charged.
Erleada (apalutamide) is an oral, second-generation androgen receptor inhibitor used to treat advanced prostate cancer in adult men. It is approved for non-metastatic castration-resistant prostate cancer (nmCRPC) and for metastatic castration-sensitive prostate cancer (mCSPC). In every case, Erleada is taken alongside ongoing hormone therapy that lowers testosterone (androgen deprivation therapy).
How Erleada Works:
Prostate cancer cells typically grow by responding to testosterone signals through androgen receptors. Erleada is a second-generation inhibitor that binds directly to these receptors, preventing the cancer cells from receiving growth instructions. This process slows the progression of the disease, even in castration-resistant cases where the cancer continues to grow despite suppressed testosterone levels.
Form and use:
The standard dosage for Erleada is 240 mg taken once daily, which consists of four 60 mg tablets. These can be taken with or without food and should be swallowed whole or crushed and mixed with applesauce if necessary. Patients should take the medication at approximately the same time each day and continue treatment until the disease progresses or side effects become too severe.
Generic availability:
As of 2026, there is no FDA-approved generic version of Erleada available in the United States. While other androgen receptor inhibitors like Xtandi (enzalutamide) and Nubeqa (darolutamide) are approved for treating prostate cancer, they are distinct medications. The clinical choice between these options depends on a patient’s specific diagnosis, treatment history, and individual tolerability.
Warnings:
Erleada is associated with serious risks, including seizures, falls, fractures, and cardiovascular or cerebrovascular events. It is taken in conjunction with ongoing hormone therapy and may lead to thyroid dysfunction or severe skin reactions. Patients should immediately report symptoms such as chest pain, sudden weakness, numbness, or any new seizures to their oncology team.
The retail price commonly runs $13,000–$15,000 per 30-day supply at the standard 240 mg daily dose. Through AffordMyPrescriptions, qualifying patients receive Erleada at no medication cost — our $69.95 monthly fee covers full advocacy and program management.
All three are second-generation androgen receptor inhibitors used in advanced prostate cancer. Erleada (apalutamide), Xtandi (enzalutamide), and Nubeqa (darolutamide) work through the same general mechanism but differ in side-effect profiles, drug-interaction patterns, and approved indications. Whether one is a better fit depends on your medical history, comorbidities, and tolerability.
Yes. Erleada is intended to be used together with ongoing hormone therapy that lowers testosterone (such as a leuprolide-type injection or, in some cases, surgical orchiectomy). Erleada works at the androgen receptor and is not a replacement for the hormone therapy your oncology team has already started.
Erleada is taken at 240 mg by mouth once daily (4 × 60 mg tablets), with or without food. Tablets should be swallowed whole or can be crushed and mixed with applesauce. Take it at roughly the same time each day. Treatment continues until disease progression or unacceptable toxicity.
Yes. Medicare Part D beneficiaries can typically qualify for Erleada Patient Assistance, especially if you face specialty-tier copays you cannot afford. The manufacturer’s commercial copay savings program is reserved for commercially insured patients only — but the underlying PAP supports Medicare patients who meet income criteria.
If your initial application is denied, we explore alternatives — the manufacturer’s copay savings program if you have commercial insurance, independent foundations such as the PAN Foundation, HealthWell Foundation, ZERO Prostate Cancer, or the Prostate Cancer Foundation, or asking your oncology team whether a different androgen receptor inhibitor (Xtandi, Nubeqa) would be appropriate. If we cannot find a path, you will not be charged our service fee.
If you are struggling with the high cost of Erleada, our team may be able to help you access assistance programs designed to make brand specialty prostate cancer therapy affordable. Check your eligibility today.
Start free by filling out a simple online form.
Our specialist will contact you for a quick welcome call.
Our team handles everything, so you can focus on your health.